BiotechTube
Home/Tilray/Denise M. Faltischek
DM

Denise M. Faltischek

Chief Strategy Officer & Head of International

Tilray

Therapeutic Areas

OncologyNeurologyInflammatory Conditions

Tilray Pipeline

DrugIndicationPhase
TLR-011 (Nabiximols)Glioblastoma MultiformePhase 2
TLR-002Pediatric EpilepsyPhase 3
TLR-003Pancreatic CancerPreclinical/Phase 1
TLR-004Inflammatory Bowel DiseasePreclinical
TLR-005Multiple Sclerosis SpasticityPhase 2
TLR-006Chronic PainPhase 2
TLR-007Anxiety DisordersPhase 1/2
TLR-008Neonatal Hypoxic-Ischemic EncephalopathyPreclinical

Leadership Team at Tilray

ID
Irwin D. Simon
Chairman, President & Chief Executive Officer
CA
Carl A. Merton
Chief Financial Officer
BM
Blair MacNeil
President, Canada
JB
Jodi Butts
Lead Independent Director
View full Tilray profile